RT Journal Article
SR Electronic
T1 An inflammatory cytokine signature helps predict COVID-19 severity and death
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.05.28.20115758
DO 10.1101/2020.05.28.20115758
A1 Diane Marie Del Valle
A1 Seunghee Kim-Schulze
A1 Hsin-Hui Huang
A1 Noam Beckmann
A1 Sharon Nirenberg
A1 Bo Wang
A1 Yonit Lavin
A1 Talia Swartz
A1 Deepu Madduri
A1 Aryeh Stock
A1 Thomas U. Marron
A1 Hui Xie
A1 Manishkumar Patel
A1 Oliver van Oekelen
A1 Adeeb Rahman
A1 Patricia Kovatch
A1 Judith A. Aberg
A1 Eric Schadt
A1 Sundar Jagannath
A1 Madhu Mazumdar
A1 Alexander Charney
A1 Adolfo Firpo-Betancourt
A1 Damodara Rao Mendu
A1 Jeffrey Jhang
A1 David Reich
A1 Keith Sigel
A1 Carlos Cordon-Cardo
A1 Marc Feldmann
A1 Samir Parekh
A1 Miriam Merad
A1 Sacha Gnjatic
YR 2020
UL http://medrxiv.org/content/early/2020/05/30/2020.05.28.20115758.abstract
AB The COVID-19 pandemic caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to more than 100,000 deaths in the United States. Several studies have revealed that the hyper-inflammatory response induced by SARS-CoV-2 is a major cause of disease severity and death in infected patients. However, predictive biomarkers of pathogenic inflammation to help guide targetable immune pathways are critically lacking. We implemented a rapid multiplex cytokine assay to measure serum IL-6, IL-8, TNF-α, and IL-1β in hospitalized COVID-19 patients upon admission to the Mount Sinai Health System in New York. Patients (n = 1484) were followed up to 41 days (median 8 days) and clinical information, laboratory test results and patient outcomes were collected. In 244 patients, cytokine measurements were repeated over time, and effect of drugs could be assessed. Kaplan-Meier methods were used to compare survival by cytokine strata, followed by Cox regression models to evaluate the independent predictive value of baseline cytokines. We found that high serum IL-6, IL-8, and TNF-α levels at the time of hospitalization were strong and independent predictors of patient survival. Importantly, when adjusting for disease severity score, common laboratory inflammation markers, hypoxia and other vitals, demographics, and a range of comorbidities, IL-6 and TNF-α serum levels remained independent and significant predictors of disease severity and death. We propose that serum IL-6 and TNF-α levels should be considered in the management and treatment of COVID-19 patients to stratify prospective clinical trials, guide resource allocation and inform therapeutic options. We also propose that patients with high IL-6 and TNF-α levels should be assessed for combinatorial blockade of pathogenic inflammation in this disease.Competing Interest StatementS.G. reports consultancy and/or advisory roles for Merck, Neon Therapeutics and OncoMed and research funding from Bristol-Myers Squibb, Genentech, Immune Design, Agenus, Janssen R&D, Pfizer, Takeda, and Regeneron.Funding StatementS.G., D.M.D.V.. S.K.-S., P.K., A.R. and M.M. were supported by NCI U24 grant CA224319. S.G. is additionally supported by grants U01 DK124165 and P01 CA190174. M.M. was supported by the fast-grant fund. The Human Immune Monitoring Center and the Institute for Healthcare Delivery Science received support from Cancer Center P30 grant CA196521.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was reviewed and approved by the Mount Sinai Institutional Review Board. A waiver of informed consent was obtained to query the patient electronic medical record. Samples for the RT-PCR SARS-CoV-2 lab test were collected via nasopharyngeal or oropharyngeal swab at one of 53 different Mount Sinai locations, representing outpatient, urgent care, emergency and inpatient facilities. Blood specimen for ELLA were collected via venipuncture within the MSHS. All specimen and imaging were collected as part of standard of care.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are not publicly available due to United States Federal Health Insurance Portability and Accountability Act (HIPAA) compliance. A de-identified dataset may be available from the corresponding author on reasonable request.